25.04.2016
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: WILEX AG successfully completes capital increase
DGAP-News: WILEX AG / Key word(s): Capital Increase
WILEX AG: WILEX AG successfully completes capital increase
25.04.2016 / 16:13
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
WILEX AG successfully completes capital increase
Munich, 25 April 2016 - The Executive Management Board of WILEX AG (ISIN
DE000A11QVV0 / WL6 / FSE and ISIN DE000A169P97 / WL6J / FSE) today decided
- with the Supervisory Board's approval - to set the final scope of the
rights issue to be executed to a total of 2,248,272 new shares.
WILEX's shareholders exercised their subscription and additional
subscription rights for 1,074,845 new no par value bearer shares at a price
of EUR 1.84 per share by the end of the subscription period on 22 April
2016. Thereby, shareholders exercised subscription rights for a total of
1,035,286 new shares. This meant that 1,212,986 new shares were available
for additional subscription by shareholders, of which 39,559 new shares
were allocated to the shareholders through their custodian banks in
connection with the capital increase. Those 1,173,427 new shares not
subscribed as part of the offer to exercise subscription and additional
subscription rights were taken over for subscription by the main
shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany,
by way of a private placement at the same price of EUR 1.84.
Accordingly, this capital increase will lift the Company's share capital by
EUR 2,248,272, from EUR 10,679,292.00 to EUR 12,927,564.00, once its
execution has been entered in the Commercial Register.
WILEX AG plans to use the expected gross proceeds from the rights issue of
EUR 4.13 million to finance the further development of the platform
technology for Antibody-Targeted Amanitin Conjugates (ATAC), to build an
own ATAC product pipeline against cancer diseases and to expand the
customer-specific research business.
The subscribed and allotted shares are expected to be delivered on 29 April
2016, but no earlier than after their admission to trading on the Regulated
Market (Prime Standard). The new shares are due to be included in trading
on 29 April 2016. All new shares carry dividend rights from 1 December
2015. Given this difference in dividend rights, the new shares will be
traded separately under the ISIN DE000A169P97 / WKN A16 9P9 until the
planned inclusion in the Company's current listing, which will take place
after the Annual General Meeting adopting resolutions regarding the
2014/2015 financial year. ODDO SEYDLER BANK AG, Frankfurt, was the sole
lead manager of the capital measures.
About WILEX
WILEX AG is a biopharmaceutical company which discontinued all clinical
development activities at its Munich site and now exercises a holding
function as the Group parent. Research and development focus on the
operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which
primarily advances the development of the innovative ADC platform
technology for Antibody-Targeted Amanitin Conjugates (ATAC technology) and
provides preclinical drug research and development services. WILEX has the
diagnostic and therapeutic drug candidates REDECTANE(R) and RENCAREX(R),
which are available for out-licensing and further development in Phase III
for external partners. WILEX is listed at the Frankfurt Stock Exchange:
ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available
at http://www.wilex.com/.
Contact IR/PRsupport WILEX AG MC Services AG Corporate Communications Katja Arnold (CIRO) Sylvia Wimmer Executive Director & Partner Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 18, 81675 Munich Email: katja.arnold[at]mc-services.euThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------------- 25.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 457435 25.04.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6